Biocytogen Pharmaceuticals-B (02315) has issued a positive profit forecast, expecting a net profit attributable to shareholders of between 236 million to 246 million yuan in the first half of the year, representing a year-on-year increase of 391.87% to 412.71%.

Biocytogen Pharmaceuticals-B (02315) announced that, according to preliminary calculations by the company's finance department, it is expected that the group will achieve operating revenue of approximately RMB 936 million to RMB 946 million in the first half of 2026. This represents an increase of RMB 315 million to RMB 325 million compared to the same period last year, resulting in a year-on-year growth of 50.80% to 52.41%. It is anticipated that the net profit attributable to the parent company owners will reach RMB 236 million to RMB 246 million in the first half of 2026, an increase of RMB 188 million to RMB 198 million compared to the same period last year, reflecting a year-on-year growth of 391.87% to 412.71%. The net profit attributable to the parent company owners, after deducting non-recurring gains and losses, is expected to be between RMB 192 million and RMB 202 million in the first half of 2026. This represents an increase of RMB 164 million to RMB 174 million compared to the same period last year, demonstrating a year-on-year growth of 574.02% to 609.04%. The main reasons for the performance changes during this period are: (1) As the biopharmaceutical industry enters a new stage of innovation-driven development, the company relies on its forward-looking R&D layout, leading products, and high-quality services, as well as a superior customer network that covers top global pharmaceutical companies and leading biotech firms. This has fully leveraged its competitive advantages and deeply embraced the business development opportunities brought by the improving industry environment. During the reporting period, the companys two major business lines achieved dual-driven growth and cross-coordination, sustaining high-speed revenue growth. (2) With the significant enhancement of the company's revenue scale and industry position, the effects of scale in production capacity and operations have accelerated. On this basis, combined with the continuous deepening of lean management, the company has effectively reduced costs and increased efficiency, driving an overall increase in gross margin. The effective reduction in expense ratios has significantly enhanced the company's profitability, leading to accelerated release of scaled profits.